Seth Hopkins PhD

Seth Hopkins, Ph.D., is Executive Director of Translational Medicine at Sunovion Pharmaceuticals Inc. In his work at Sunovion, he has led and advanced new treatments for CNS disorders from discovery through to regulatory submissions. Seth has served in a variety of roles including computational chemistry, pharmacology, and preclinical and clinical development. In his current role, he is advancing programs through clinical development applying clinical pharmacology, experimental medicine, neuroimaging, modeling, and simulations. At Sunovion his current research interest is in the application of advanced mathematics and analytics to the clinical development of novel treatments for psychiatric disorders. Seth was a key contributor to the initiation, clinical development, and regulatory submissions of dasotraline and SEP-363856. Seth completed his postdoctoral training at the University of California San Francisco and his Ph.D. in biophysics from the University of Pennsylvania.